|
MY193765A
(en)
|
2015-02-16 |
2022-10-27 |
Univ Queensland |
Sulfonylureas and related compounds and use of same
|
|
IL293873B2
(en)
|
2015-10-20 |
2024-03-01 |
Magic Leap Inc |
Selecting virtual objects in a three-dimensional space
|
|
EP4418070A3
(en)
|
2016-03-31 |
2024-11-13 |
Magic Leap, Inc. |
Interactions with 3d virtual objects using poses and multiple-dof controllers
|
|
JP7163293B2
(ja)
|
2017-01-23 |
2022-10-31 |
ジェネンテック， インコーポレイテッド |
インターロイキン－１活性の阻害剤としての化学化合物
|
|
HRP20220195T1
(hr)
|
2017-07-07 |
2022-04-15 |
Inflazome Limited |
Novi spojevi sulfonamid karboksamida
|
|
CN117209447A
(zh)
|
2017-07-24 |
2023-12-12 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
EP3658538B1
(en)
*
|
2017-07-24 |
2023-04-19 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3668843A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
TW201910317A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
PE20200758A1
(es)
|
2017-08-15 |
2020-07-27 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
CN111417622A
(zh)
*
|
2017-10-17 |
2020-07-14 |
诺华炎症研究公司 |
用于治疗与nlrp活性相关的病症的磺胺类及其组合物
|
|
CA3078195A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166632A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166633A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
US20200399242A1
(en)
*
|
2018-03-02 |
2020-12-24 |
Inflazome Limited |
Novel compounds
|
|
EP3759090A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
US11884645B2
(en)
|
2018-03-02 |
2024-01-30 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
US11905252B2
(en)
|
2018-03-02 |
2024-02-20 |
Inflazome Limited |
Compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
US20210261512A1
(en)
|
2018-05-04 |
2021-08-26 |
Inflazome Limited |
Novel compounds
|
|
CA3103664A1
(en)
|
2018-07-03 |
2020-01-09 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
|
US20210395241A1
(en)
|
2018-07-03 |
2021-12-23 |
Novartis Ag |
Nlrp modulators
|
|
PE20211811A1
(es)
|
2018-07-20 |
2021-09-14 |
Hoffmann La Roche |
Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
|
|
CA3104199A1
(en)
|
2018-07-20 |
2020-01-23 |
F. Hoffmann-La Roche Ag |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
PE20211333A1
(es)
|
2018-08-15 |
2021-07-22 |
Inflazome Ltd |
Compuestos de sulfonamidaurea novedosos
|
|
EP3870168A1
(en)
*
|
2018-10-24 |
2021-09-01 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
US12134611B2
(en)
|
2018-11-13 |
2024-11-05 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
ES2974842T3
(es)
*
|
2018-11-13 |
2024-07-01 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
|
|
CN113227055A
(zh)
*
|
2018-11-16 |
2021-08-06 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
WO2020154321A1
(en)
*
|
2019-01-22 |
2020-07-30 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
EP3983388A1
(en)
*
|
2019-06-12 |
2022-04-20 |
Nodthera Limited |
Sulfonamide derivatives and uses thereof
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
|
CA3151865A1
(en)
|
2019-07-17 |
2021-01-21 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms)
|
|
JP7595642B2
(ja)
*
|
2019-07-17 |
2024-12-06 |
ズーマゲン バイオサイエンシーズ エルティーディー |
Ｎｌｒｐ３モジュレーター
|
|
EP4013762A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
JP2023518044A
(ja)
|
2020-03-16 |
2023-04-27 |
ズーマゲン バイオサイエンシーズ エルティーディー |
Ｎｌｒｐ３モジュレーター
|
|
WO2021188052A1
(en)
*
|
2020-03-19 |
2021-09-23 |
Nanyang Technological University |
Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation
|
|
AR121669A1
(es)
*
|
2020-03-27 |
2022-06-29 |
Astellas Pharma Inc |
Compuesto de piridazina sustituida
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
WO2021249337A1
(zh)
*
|
2020-06-11 |
2021-12-16 |
南京明德新药研发有限公司 |
二甲基亚磺酰亚胺衍生物
|
|
CA3178361A1
(en)
|
2020-06-19 |
2021-12-23 |
Emanuele Gabellieri |
Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN117222626A
(zh)
|
2021-04-28 |
2023-12-12 |
安斯泰来制药株式会社 |
取代三嗪化合物
|
|
JPWO2023003002A1
(enExample)
|
2021-07-21 |
2023-01-26 |
|
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
US20250109126A1
(en)
|
2021-12-22 |
2025-04-03 |
Ac Immune Sa |
Dihydro-oxazol derivative compounds
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CN119998284A
(zh)
|
2022-07-28 |
2025-05-13 |
Ac免疫有限公司 |
新化合物
|
|
TW202432551A
(zh)
|
2022-10-26 |
2024-08-16 |
日商安斯泰來製藥股份有限公司 |
稠環嗒嗪衍生物
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
KR20250170045A
(ko)
*
|
2023-03-17 |
2025-12-04 |
벤투스 테라퓨틱스 유에스 인코포레이티드 |
Nlrp3를 억제하기 위한 아마이드 유도체 및 이의 용도
|
|
WO2024249539A1
(en)
|
2023-06-02 |
2024-12-05 |
Merck Sharp & Dohme Llc |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
TW202545527A
(zh)
|
2024-01-16 |
2025-12-01 |
英商諾得瑟拉公司 |
Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|